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Abstract: COVID-19 infection causes acute lung injury, resulting from aggressive inflammation 29 
initiated by viral replication. There has been much speculation about the potential role of non-30 
steroidal inflammatory drugs (NSAIDs), which increase the expression of angiotensin converting 31 
enzyme 2 (ACE2), a binding target for SARS-CoV-2 to enter the host cell, which could lead to poorer 32 
outcomes in COVID-19 disease. The aim of this study was to examine the association between routine 33 
use of NSAIDs and outcomes in hospitalized patients with COVID-19 infection.  34 
 This was a multi-centre, observational study, with data collected from adult patients with 35 
COVID-19 admitted to eight UK hospitals. Of 1222 patients eligible to be included, 54 (4.4%) were 36 
routinely prescribed NSAIDs prior to admission. Univariate results suggested a modest protective 37 
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effect from the use of NSAIDs, but in the multivariable analysis, there was no association between 38 
prior NSAID use and time-to-mortality (adjusted HR [aHR] = 0.89, 95%CI 0.52-1.53, p=0.67) or length 39 
of stay (aHR 0.89, 95% CI 0.59-1.35, p=0.58). 40 
 This study found no evidence that routine NSAID use was associated with higher COVID-19 41 
mortality in hospitalized patients, therefore patients should be advised to continue taking these 42 
medications until further evidence emerges. Our findings suggest that NSAID use might confer a 43 
modest benefit with regards to survival. However, as this finding was underpowered further 44 
research is required. 45 
 46 
Keywords: covid-19; SARS-CoV-2; non-steroidal anti-inflammatory drugs; NSAIDs  47 
 48 
1. Introduction 49 
The pattern of acute lung injury seen in SARS-CoV-2 (commonly referred to as COVID-19) infection 50 
is thought to be a result of aggressive inflammation initiated by viral replication, however the exact 51 
pathophysiology behind this phenomenon remains largely unknown [1]. Following recognition that 52 
the angiotensin converting enzyme 2 receptor (ACE2) serves as a binding site for SARS CoV-2 to 53 
enter the host cell, a number of European authorities, including those in France and Belgium, issued 54 
federal reports suggesting that the use of non-steroidal inflammatory drugs (NSAIDs) in COVID-19 55 
infection might adversely affect patients’ clinical course and recovery [2]. There remains, however, a 56 
considerable uncertainty regarding the use of common NSAIDs and their effect on COVID-19.  57 
 58 
NSAIDs are one of the most commonly prescribed and used pain medications worldwide, for both 59 
acute pain and chronic conditions such as rheumatological diseases and osteoarthritis [3,4], with 60 
analgesic, anti- inflammatory and anti-pyretic properties. Risks of NSAID use have been well studied 61 
in the general population, with particular focus on the association between their long-term use and 62 
increased risk of upper gastrointestinal effects (e.g. ulceration, bleeding), renal impairment and 63 
arterial thrombotic events (e.g. myocardial infarction, stroke) [4]. It has been speculated that 64 
ibuprofen may upregulate the cellular expression of (ACE2) [5], and in the context of COVID-19 it is 65 
therefore postulated that NSAID use could result in a higher viral infective load in respiratory tract. 66 
More recent work has also implicated NSAIDs in their association with high rates of complication 67 
(effusion, empyema, dissemination of infection) after acute respiratory tract infection [6,7], via the 68 
mechanism of NSAID mediated cyclo-oxygenase (COX) inhibition. It has been proposed that the 69 
inhibition of COX enzymes reduces recruitment of polymorphonuclear cells and inhibits synthesis of 70 
lipoxins and resolvins, ultimately delaying the resolution of inflammation.  71 
 72 
However, there exists a conflict of opinion within the literature with regard to coronaviruses and 73 
very little research has been conducted to date. In vitro studies of the earlier SARS-CoV infection in 74 
animal models and human lung epithelium found indomethacin to have potent antiviral activity by 75 
inhibiting viral RNA synthesis [8], an effect that was independent of COX inhibition. Whilst the anti-76 
inflammatory properties of NSAIDs are well known, it is unclear what, if any, their effect is on 77 
outcomes in acute respiratory tract infection.  78 
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Available published evidence is specifically lacking in describing outcomes for patients with COVID-79 
19 infection who are NSAID users. The primary aim of this study is therefore to examine the 80 
association between prior routine use of NSAIDs and mortality and length of stay in patients 81 
admitted to hospital with COVID-19.  82 
 83 
2. Methods  84 
2.1 Study population  85 
The study population was drawn from the COPE study (COVID-19 in Older People study) [9]. COPE 86 
study is a multicentre, observational study governed by the Older Persons Surgical Outcome 87 
Collaborative (OPSOC; www.opsoc.eu), our existing academic network of clinical centres. OPSOC 88 
runs a well-established programme of research with experience in collecting epidemiological data for 89 
both academic and service evaluation purposes. In the current study, a total of eight UK centres were 90 
included. They were all involved in delivery of unscheduled, in-patient treatment to patients with 91 
COVID-19. Data were gathered between 6th March and 28th April 2020.  Patient outcomes were up 92 
to 28th April 2020. Detailed description of the study protocol and data collection methods has been 93 
previously reported [9]. 94 
 95 
In brief, data collection was undertaken prospectively using a standardised, computerised case 96 
report. This was populated after reviewing of patients’ individual paper records, prescription 97 
administration records and information from electronic records. Each site’s principal investigator 98 
supervised study personnel collecting data at a local level, all of whom had completed data collection 99 
training prior to their involvement in the study. Data was recorded securely at each site by adherence 100 
to data protection policy, and collated data was ultimately transferred in an anonymised format to 101 
King’s College London for statistical analysis.  102 
 103 
2.2 Participants 104 
Patients aged 18 years or older who were admitted to hospital with a clinical or laboratory confirmed 105 
diagnosis of COVID-19 were included. Clinical diagnoses were made by clinicians at each site, based 106 
on signs, symptoms and/or radiological appearance consistent with COVID-19, whist laboratory 107 
confirmed diagnoses required positive PCR results from a swab for SARS-CoV-2. There were no 108 
exclusion criteria.  109 
 110 
2.3 End points 111 
The primary endpoint was the time-to-mortality from the date of admission or date of diagnosis, 112 
when the patient was diagnosed with COVID-19 five or more days after admission. Secondary 113 
outcomes included day 7 mortality and the time from admission or diagnosis (if diagnosed minimum 114 
of five days after admission) to discharge (length of stay). 115 
 116 
2.4 Exposure 117 
Data on the use of NSAIDs, including the number, type and dose of anti-inflammatory that each 118 
patient was taking prior to admission were collected from admission records and from online GP 119 
prescription records. NSAIDs included in the data collection were: propionic acid derivatives such 120 
as ibuprofen and naproxen, diclofenac, an acetic acid derivative and selective COX-2 inhibitors such 121 
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 4 of 16 
 
as celecoxib. Topical NSAIDs such as ibuprofen gels were not included due to their low level of 122 
systemic absorption and consequential limited systemic effects [10,11]. Low dose aspirin was not 123 
included as an NSAID in our data collection, as although it is a COX-inhibitor its effects are primarily 124 
anti-platelet at low doses, with minimal anti-inflammatory effects. History of coronary artery disease 125 
was included in the covariate data collection and adjusted for, and the majority of these patients will 126 
be taking aspirin.  127 
 128 
2.5 Covariates  129 
Additional clinical demographics collected included: age; sex; smoking status (current, previous, 130 
never); C-reactive protein (CRP) on admission; reduced renal function (eGFR <60 on admission) and 131 
the presence of comorbidities including diabetes mellitus, hypertension, and coronary artery disease 132 
(CAD).  133 
 134 
2.6 Statistical analysis  135 
Baseline demographic and clinical characteristics were compared by in hospital mortality status, and 136 
patients who were taking an NSAID versus those who were not. Time to-event outcomes (death, or 137 
discharge) were analysed with mixed-effects multivariable Cox’s proportional baseline hazards 138 
models. The analyses were fitted with a random intercept to account for hospital variation, and 139 
adjusted for the base model of: NSAID prescribed (yes/no); patient age group; sex; smoking status; 140 
CRP; diabetes; hypertension; coronary artery disease; reduced renal function (eGFR<60). The 141 
adjusted hazard ratios (aHR) were estimated with associated 95% confidence intervals (95%CI). The 142 
baseline proportionality assumption was tested visually with log-log residuals. Each time to event 143 
analysis was reported with a Kaplan Meier survival plot. Day 7 mortality was analysed using a 144 
mixed-effects multivariable logistic model, fitting each hospital as a random intercept effect, and 145 
adjusted with covariates consistent with the time-to-event analyses. The adjusted odds ratio (aOR) 146 
were estimated and presented with corresponding 95% confidence interval (95%CI). Missing data 147 
were explored for patterns of missingness. Subgroup analyses were carried out to explore potentially 148 
moderating effects of NSAID use within different subgroups stratified by: age group; sex; smoking 149 
status; diabetes; hypertension; coronary artery disease; and renal impairment. Analysis was carried 150 
out using Stata version 15 [12] Kaplan Meier survival plots were visualised in R [13], with packages 151 
survival [14] and survminer [15].   152 
 153 
Permission to undertake the study was received from The Health Research Authority (20/HRA/1898); 154 
Cardiff University acted as study sponsor.  155 
3. Results 156 
Data were collected from 1,222 patients with COVID-19 across eight UK sites, of whom 56.5% (n=690) 157 
were male. 4.4% of patients (n=54) were prescribed routine NSAIDs prior to admission. There were 158 
19 patients with missing CRP data, these were inputted as CRP<40, and a further 20 patients with 159 
missing smoking status who were recorded as ‘never smokers’. Overall in-hospital mortality was 160 
29.3% (n=358), varying from 12.2-43.9% across hospital sites. In-hospital mortality was 25.9% (n=14) 161 
in the NSAID users and 29.5% (n=344) among the non-users (p=0.578). In-hospital mortality was 162 
higher in older age groups (39% in patients aged ≥80 years; 34.3% in those aged 65-79 years; 12.9% in 163 
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patients aged <65 years) and with the presence of co-morbidities including diabetes (32.4% in patients 164 
with diabetes vs. 28.1% in those without), hypertension (32.6% vs. 25.7%), coronary artery disease 165 
(39.2% vs. 26.3%) and reduced renal function (eGFR<60) on admission (38.7% vs. 23.1%). A complete 166 
breakdown of demographics and clinical characteristics by in-hospital mortality is shown in Table 1.  167 
 168 
Table 1: Demographics, comorbidities and NSAID usage, by in hospital mortality 169 
 Alive Dead Total p-value& 
 (n=864) (n=358) (n=1222)  
     NSAID Prescription    
0.578 No 824 (70.6) 344 (29.5) 1168 (95.6) 
Yes 40 (74.1) 14 (25.9) 54 (4.4) 
    
Sites    
<0.001 
    
Hospital A 119 (77.8) 34 (22.2) 153 (12.5) 
Hospital B 33 (76.7) 10 (23.3) 43 (3.5) 
Hospital C 108 (87.8) 15 (12.2) 123 (10.1) 
Hospital D 254 (66.8) 126 (33.2) 380 (31.1) 
Hospital E 76 (67.9) 36 (32.1) 112 (9.2) 
Hospital F 138 (56.1) 108 (43.9) 246 (20.1) 
Hospital G 100 (87.0) 15 (13.0) 115 (9.4) 
Hospital H 36 (72.0) 14 (28.0) 50 (4.1) 
    Age    
<0.001 Under 65 yrs 337 (87.1) 50 (12.9) 387 (31.7) 
65 to 79 yrs 266 (65.7) 139 (34.3) 405 (33.1) 
Over 80 yrs 261 (60.7) 169 (39.3) 430 (35.2) 
     Sex    
0.625 Female 380 (71.4) 152 (28.6) 532 (43.5) 
Male 484 (70.1) 206 (29.9) 690 (56.5) 
     
Smoking Status    
0.049 
Never smokers 453 (73.2) 166 (26.8) 619 (50.7) 
Ex-smokers 325 (66.7) 162 (33.3) 487 (39.9) 
Current smokers 74 (77.1) 22 (22.9) 96 (7.8) 
Missing 12 8 20 
     
Diabetes     
0.100 No 638 (71.9) 249 (28.1) 887 (72.6) 
Yes 223 (67.6) 107 (32.4) 330 (27.0) 
Missing 3 2 5 
     
Hypertension 
   
0.008 No 
448 (74.3) 155 (25.7) 603 (49.4) 
Yes 414 (67.4) 200 (32.6) 614 (50.3) 
Missing 2 3 5 
    
Coronary Artery disease    
<0.001 No 696 (73.7) 248 (26.3) 944 (77.3) 
Yes 166 (60.8) 107 (39.2) 273 (22.3) 
Missing 2 3 5 
     Elevated CRP (>40)     
No 282 (84.4) 52 (15.6) 334 (27.3) 
<0.001 Yes 571 (65.7) 298 (34.3) 869 (72.7) 
Missing 11 8 19 
Renal function (eGFR<60)     
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No 568 (76.9) 171 (23.1) 739 (60.5) 
<0.001 Yes 290 (61.3) 183 (38.7) 473 (38.7) 
Missing 6 4 10 
&Chi-squared was carried out between clinical characteristics and mortality  170 
 171 
Overall NSAID use in the study population was 4.4% (n=54), ranging from 2.6-18.6% across the 172 
eight hospital sites. Pre-admission NSAID use was higher in the younger age groups (<65 years 6.5%; 173 
65-79 years 4.2%; ≥80 years 2.8%) and lower in patients with co-morbidities including diabetes (3.3% 174 
in diabetic patients vs 4.9% in non-diabetics), hypertension (2.8% vs 6.1%), coronary artery disease 175 
(3.3% vs 4.8%) and reduced renal function (3.0% vs 5.4%). The routine prescription of NSAIDs was 176 
higher in those with an elevated CRP on admission; 5.1% of patients with an elevated CRP (>40mg.dl-177 
1) were prescribed routine NSAIDs prior to admission, compared to 3% of those without an elevated 178 
CRP. Full patient demographics and clinical characteristics by NSAID use is shown in Supplementary 179 
Table A1. 180 
3.1. Outcome analysis 181 
The primary endpoint was time to mortality, the Kaplan Meier Survival plot suggested a modest 182 
protective effect due to NSAID use (Figure 1, Kaplan Meier curves), but in the crude analysis with 183 
95%CI, we found no association between the routine use of NSAIDs, hazard ratio (HR) = 0.82 (95%CI 184 
0.48-1.40, p=0.46, Table 2; indicated by overlapping shaded areas in Figure 1). Important covariates 185 
which have previously been linked to poorer outcomes in COVID-19 disease, were associated with a 186 
reduced time-to-mortality. These included: advancing age (compared to patients aged <65 years: 187 
patients aged 65-79 years, HR=3.21, 95%CI 2.29-4.51; patients aged over 80 years, HR=3.94, 95%CI 188 
2.52-5.50); reduced renal function (eGFR <60) on admission (HR=1.80, 95%CI 1.45-2.24, p<0.001), and 189 
the presence or history of coronary artery disease (HR=1.47, p=0.001) and hypertension (HR=1.27, 190 
95%CI 1.03-1.58, p=0.03).  191 
 192 
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Figure 1: NSAID use and Mortality (shaded areas indicate 95% confidence intervals): 193 
 194 
 195 
 196 
In the multivariable analysis, there was no association between pre-admission NSAID use and 197 
time-to-mortality (adjusted HR [aHR] = 0.89, 95%CI 0.52-1.53, p=0.67, Table 2). Advancing age (65-79 198 
vs under 65, aHR=3.14, 95%CI 2.20-4.48, p<0.001; over 80 vs under 65; aHR=4.00, 95%CI 2.81-5.71, 199 
<0.001), elevated CRP (>40mg/dl; aHR=2.75, 95%CI 2.01-3.76, p<0.001) and reduced renal function on 200 
admission (eGFR <60; aHR=1.40, 95%CI 1.11-1.75, p=0.004) were associated with mortality. 201 
 202 
 203 
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Table 2: Time to mortality. Crude and multivariable analysis 204 
 Crude Hazard Ratio (HR) Adjusted Hazard Ratio (aHR)& 
 (n=1,181) (n=1,167) 
 HR, (95%CI) p-value aHR, (95%CI) p-value 
     
NSAID 0.82 (0.48-1.40) 0.46 0.89 (0.52-1.53) 0.67 
     
Age     
Under 65 - Ref     -  Ref   - 
65 to 79 3.21 (2.29-4.51) <0.001 3.14 (2.20-4.48) <0.001 
Over 80 3.94 (2.82-5.50) <0.001 4.00 (2.81-5.71) <0.001 
     
Sex (Female)     -    Ref        Ref     - 
Male 0.88 (0.71-1.10) 0.25 0.88 (0.70-1.11) 0.28 
     Smoking status 
(Never) 
  
Ex-smokers 1.24 (1.0-1.55) 0.06 1.02 (0.80-1.28) 0.92 
Current smokers 0.90 (0.56-1.42) 0.62 1.11 (0.68-1.82) 0.66 
     
Elevated CRP (>40) 2.24 (1.65-3.05) <0.001 2.75 (2.01-3.76) <0.001 
     
Patients with 
diabetes 
1.09 (0.87-1.38) 0.45 1.03 (0.81-1.32) 0.80 
     
Patients with CAD 1.47 (1.16-1.87) 0.001 1.09 (0.84-1.40) 0.53 
     
Patients with 
hypertension 
1.27 (1.03-1.58) 0.03 0.97 (0.77-1.22) 0.81 
     
Patients with 
reduced renal 
function (eGFR<60) 
    
1.80 (1.45-2.24) <0.001 1.40 (1.11-1.76) 0.004 
&The multivariable mixed-effects analysis was adjusted for: age group; sex; smoking; CRP; diabetes; CAD; hypertension; and 205 
renal function 206 
 207 
In the analysis for secondary outcomes, no association was found between pre-admission 208 
NSAID use and day-7 mortality (adjusted Odds Ratio (aOR) = 0.79, p=0.60, Table 3) or time-to-209 
discharge (aHR=0.89, 95% CI 0.59-1.35, p=0.58, Table 3). Day-7 mortality was associated with older 210 
age (compared to patients aged <65 years; 65-79 years aOR=3.80, p<0.001; ≥80 years aOR=5.14, 211 
p<0.001), elevated CRP on admission (aOR=4.91, p<0.001) and reduced renal function (aOR=2.02, 212 
p<0.001). An increased length of stay was associated with older age and elevated CRP on admission 213 
(see Table 3). 214 
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 215 
Table 3: Day 7 mortality and Time to discharge. Multivariable analysis  216 
 Adjusted Odds Ratio (OR) Adjusted Hazard Ratio (aHR)& 
 (n=1158) (n=1167) 
 aOR, (95%CI) p-value aHR, (95%CI) p-
value 
     
NSAID 0.79 (0.32-1.92) 0.602 0.89 (0.59-1.35) 0.58 
     
Age     
Under 65 - Ref     -  Ref   - 
65 to 79 3.80 (2.26-6.37) <0.001 0.76 (0.61-0.95) 0.02 
Over 80 5.14 (3.04-8.69) <0.001 0.56 (0.44-0.73) <0.001 
     
Sex (Female) - Ref     -    Ref   - 
Male 0.81 (0.57-1.14) 0.227 0.92 (0.76-1.11) 0.37 
     
Smoking status (Never)   
Ex-smokers 1.17 (0.83-1.67) 0.372 0.95 (0.78-1.15) 0.61 
Current smokers 1.12 (0.54-2.33) 0.765 1.04 (0.73-1.48) 0.84 
     
Elevated CRP (>40) 4.91 (2.99-8.06) <0.001 0.69 (0.57-0.84) <0.001 
     
Patients with diabetes 1.04 (0.71-1.52) 0.838 0.84 (0.68-1.04) 0.12 
     
Patients with CAD 1.46 (1.00-2.13) 0.051 1.12 (0.88-1.42) 0.36 
     
Patients with 
hypertension 
0.78 (0.55-1.10) 0.157 0.95 (0.79-1.16) 0.63 
     
Patients with reduced 
renal function (eGFR<60) 
    
2.02 (1.42-2.86) <0.001 0.92 (0.75-1.13) 0.58 
&The multivariable mixed-effects analysis was adjusted for: age group; sex; smoking; CRP; diabetes; CAD; hypertension; and 217 
renal function 218 
 219 
Supplementary figures A1-A3 show subgroup analysis for patients prescribed NSAIDs, in 220 
relation to the three endpoints time-to-mortality, 7-day mortality and length of stay. Hazards ratios 221 
and odds ratios are adjusted for age group, sex, smoking status and co-morbidities. Due to the small 222 
number of NSAID users in our study population these analyses were underpowered and should be 223 
interpreted with caution and with a large degree of uncertainty.  224 
 225 
4. Discussion 226 
To the best of our knowledge, this study is the first to report on routine NSAID use and outcomes in 227 
hospitalized patients with COVID-19. We found that routine use of NSAIDs might confer a modest 228 
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survival benefit and lit is not associated with poorer outcomes. Uncertainty and speculation have 229 
surrounded this topic, and existing literature primarily references experience of these drugs in the 230 
setting of previous respiratory virus outbreaks [16]. Therefore, our findings provide novel 231 
information at a time where there is a significant lack of evidence and high demand for knowledge.  232 
 233 
Whilst systematic reviews have concluded that there is insufficient evidence to determine the effect 234 
of NSAIDs in COVID-19 infection [16-19], advising against drastic changes to drug regimens, 235 
alternative literature advises that NSAIDs should be avoided until evidence emerges [20]. Many of 236 
the studies referenced within literature reviews are in relation to respiratory viruses other than SARS-237 
CoV-2. It is thought that the pathophysiology and transmission of COVID-19 even shows differences 238 
in behaviour from other viruses within its family, such as severe acute respiratory virus (SARS) and 239 
Middle Eastern respiratory syndrome (MERS) [19]. Therefore, the findings of these studies may not 240 
be applicable in COVID-19 infection. However, very recently Rinott et al [21] published a 241 
retrospective cohort study of 403 cases of COVID-19 patients, recruiting those who used “any 242 
medication containing ibuprofen, paracetamol or dipyrone starting a week before diagnosis of 243 
COVID-19”. Their conclusions therefore address the issue of acute use of NSAIDs, however found 244 
no significant association between ibuprofen usage and clinical outcomes (including mortality) when 245 
comparing the NSAID with cohorts using paracetamol or no- antipyretic. 246 
 247 
Pre-admission NSAID use was lower in older age groups, which is in line with a recent European 248 
study of NSAID epidemiology [22]. NSAIDS account for 25% of adverse drug events reported in the 249 
United Kingdom [23], and it is thought that the elderly are more susceptible to the adverse effects of 250 
these drugs [4]. Conversely, the higher percentage of NSAID use in younger adults in this study may 251 
reflect their relative co-morbidity and subsequent susceptibility to hospitalization as a result of 252 
COVID-19. 253 
 254 
Pre-admission NSAID use was also found to be lower in patients with co-morbidities across all age 255 
groups. This may be due to the relative contraindication of NSAIDs in these patients [24], and 256 
potential for drug interactions [25].  This low prevalence of NSAIDs routine use may be related to 257 
high proportion of patients with COVID-19 with background respiratory illness, where their use may 258 
be contraindicated. In analysis of biochemical markers, the routine prescription of NSAIDs was 259 
associated with elevated CRP on admission. This is expected, and is likely a reflection of pre- existing 260 
inflammatory conditions that require regular NSAID usage in this patient group in addition to 261 
COVID-19 infection. 262 
 263 
Limitations of this study include a relatively small number of NSIAD users in our cohort thus study 264 
may be underpowered.  It is possible that patients who have been using over-the-counter NSAIDs 265 
have not been captured. Conversely, as we collected data from prescriptions it is possible that some 266 
of the patients prescribed NSAIDs were not actually taking them in the days or weeks leading up to 267 
admission. We did not collect data on indication for, or duration of use of the agents, hence we cannot 268 
rule out possible confounding by indication.  269 
 270 
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 11 of 16 
 
There are intrinsic limitations associated with any observational study. However, the prospective 271 
relationship described reduces the possibility of reverse causality, whilst unselected cohort design 272 
reduced the selection bias. This study did not take into consideration a proportion of patients who 273 
were discharged from, or died in the Emergency Department or those patients with COVID-19 who 274 
remained in the community and were not treated in hospital. It is worth highlighting that our results 275 
specifically apply to the routine use of NSAIDs in patients who then develop COVID-19 infection. 276 
Our results therefore do not signify the safety of acute use of NSAIDs in the context of COVID-19 277 
disease. This calls for future work examining the relationship between NSAID usage, by indication 278 
and duration as well as routine vs. acute usage, and mortality in Covid-19 in a high-powered study.   279 
 280 
There are several strengths to our study. This was a multi-centre, prospective study, providing a large 281 
study population, which included patients from a range of specialties including medicine, surgery 282 
and medicine for the elderly. Through the inclusion of eight UK sites, the data are representative of 283 
populations across England, Scotland and Wales. Data was collected by trained personnel from paper 284 
and electronic records and prescription charts, which has resulted in minimal missing data.  285 
 286 
This study has a number of direct implications on both clinical practice and research. Based on our 287 
results, patients and clinicians should not associate the routine use of NSAIDs with an increased risk 288 
of mortality in COVID-19 disease, and so we recommend that patients continue to comply with their 289 
baseline drug regimen. The association between NSAIDs and mortality in patients with COVID-19 290 
warrants investigation via randomised controlled trials, as a method of further examining the 291 
potential beneficial effects that this study has suggested. Indeed, the LIBERATE Trial in COVID-19 292 
[26] is an ongoing, multi-centre randomised controlled trial into lipid ibuprofen versus standard of 293 
care for acute hypoxic respiratory failure due to COVID-19. This is primarily in a critical care setting. 294 
However future investigation should not only concentrate on the use of NSAIDs as a therapeutic 295 
option, but continue to explore the effects of pre-admission NSAID use on outcomes and mortality 296 
in the general population affected by COVID-19. Future, higher powered studies would more reliably 297 
comment on the association of type, dose and duration of NSAID therapy with these important 298 
outcomes. 299 
 300 
Our findings show no significant negative effect of routine NSAID use on mortality in patients with 301 
Covid-19 infection. Indeed, a modest beneficial effect of routine NSAID use on mortality may well 302 
exist, however cannot be concluded from the evidence presented here. This study has provided novel 303 
information into the impact of NSAID use and outcomes of COVID-19 disease, during a pandemic 304 
where there has been much uncertainty. Further evidence is required to explore this possible 305 
correlation and subsequently guide public health policy.    306 
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Appendix 324 
Supplementary Table A1: Demographics and comorbidities, by NSAID Use 325 
 326 
 No Yes Total 
Sites (n=1168) (n=54)  
    Hospital A 146 (95.4) 7 (4.6) 153 (12.5) 
Hospital B 35 (81.4) 8 (18.6) 43 (3.5) 
Hospital C 117 (95.1) 6 (4.9) 123 (10.7) 
Hospital D 366 (96.3) 14 (3.7) 380 (31.1) 
Hospital E 109 (97.3) 3 (3.0) 112 (9.2) 
Hospital F 235 (95.5) 11 (4.5) 246 (20.1) 
Hospital G 112 (97.4) 3 (2.6) 115 (9.4) 
Hospital H 48 (96.0) 2 (4.0) 50 (4.1) 
    Age    
Under 65 yrs 362 (93.4) 25 (6.5) 387 (31.7) 
65 to 79 yrs 388 (95.8) 17 (4.2) 405 (33.1) 
Over 80 yrs 418 (97.2) 12 (2.8) 430 (35.2) 
    Sex    
Female 503 (94.6) 29 (5.5) 532 (43.5) 
Male 665 (96.4) 25 (3.6) 690 (56.5) 
    Smoking Status    
Never smokers 585 (94.5) 34 (5.5) 619 (50.7) 
Ex-smokers 475 (97.5) 12 (2.5) 487 (39.9) 
Current smokers 88 (91.7) 8 (8.3) 96 (7.9) 
Missing 20 0 20 
    
Diabetes     
No 844 (95.2) 43 (4.9) 887 (72.6) 
Yes 319 (96.7) 11 (3.3) 330(27.0) 
Missing 5 0 5 
    
Hypertension 
   
No 
566 (93.9) 37 (6.1) 603 (49.4) 
Yes 597 (97.2) 17 (2.8) 614 (50.3) 
Missing 5 0 5 
    
Coronary Artery disease    
No 899 (95.2) 45 (4.8) 944 (77.3) 
Yes 264 (96.7) 9 (3.3) 273 (22.3) 
Missing 5 0 5 
    Elevated CRP (>40)    
No 324 (97.0) 10 (3.0) 334 (27.3) 
Yes 825 (94.9) 44 (5.1) 888 (71.1) 
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Missing 19 0 19 
Renal function (eGFR<60)     
No 699 (94.6) 10 (5.4) 739 (60.5) 
Yes 459 (97.0) 14 (3.0) 473 (38.7) 
Missing 10 0 10 
    
 327 
Supplementary Figure A1: Subgroups – Time to Mortality, Adjusted Hazard Ratio are presented 328 
from the Multivariable Cox PH model. 329 
 330 
Note: Multivariable analyses adjusted for age group, sex, smoking status, hypertension, diabetes, CAD, kidney 331 
function, and elevated CRP 332 
 333 
Supplementary Figure A2: Subgroup Analysis, Day-7 mortality. Mixed effects Logistic regression, 334 
Presenting the adjusted odds ratio from the logistic regression models.   335 
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 336 
Note: Multivariable analyses adjusted for age group, sex, smoking status, hypertension, diabetes, CAD, kidney 337 
function, and elevated CRP 338 
 339 
Supplementary Figure A3: Subgroups – Time to Discharge, Adjusted Hazard Ratio are presented 340 
from the Multivariable Cox PH model. 341 
 342 
Note: Multivariable analyses adjusted for age group, sex, smoking status, hypertension, diabetes, CAD, kidney 343 
function, and elevated CRP 344 
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